No. There is no single cell therapy proven to treat every disease. A treatment may help more than one condition, but evidence for one use does not establish that it works for another. If a clinic offers the same infusion for several unrelated diseases, ask for human evidence for each diagnosis, using the same cell product and route.
Blood stem cell transplantation can restore blood production after intensive cancer treatment. Ryoncil, a different type of cell therapy, received U.S. approval on December 18, 2024 for children aged 2 months and older with steroid-refractory acute graft-versus-host disease. Neither treatment establishes that a general stem cell infusion can treat arthritis, diabetes, Parkinson’s disease, autism, or aging. Their uses depend on the condition, patient group, and treatment protocol Stem cell transplantFda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.

Why one cell type cannot treat everything
Stem cells are not interchangeable. Blood-forming stem cells produce blood cells. Adult stem cells generally have a more limited range of possible cell types than pluripotent stem cells, which can give rise to the body’s cell types. That laboratory potential is not evidence that a prepared cell treatment will safely repair any damaged organ Stc basics.
Mesenchymal stromal cells, or MSCs, are different from blood-forming stem cells. Ryoncil contains MSCs expanded from healthy adult donors’ bone marrow. Its label says the mechanism of action is unclear but may involve effects on the immune system. It also states that no pharmacokinetic studies have been performed; that is not proof that the infused cells reach or rebuild any particular organ FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display.
Delivery matters too. Infused blood-forming cells can settle in the bone marrow and produce blood cells. A corneal cell sheet, by contrast, is transplanted onto the eye surface. Success with either approach does not establish that a drip in the arm will repair a knee, brain, or pancreas Stem cell transplant000283257.pdf.
What established treatments actually cover
Hematopoietic stem cell transplantation, or HSCT, is used for selected blood cancers, blood disorders, and immune disorders. It is a treatment approach, not one universal commercial product. Eligibility depends on the diagnosis, disease status, available donor cells, previous treatment, and overall health. The infusion itself usually takes 1–5 hours; immune recovery can take several months after an autologous transplant using your own cells and 1–2 years after an allogeneic transplant using donor cells Stem cell transplant. The differences between your own cells and donor cells matter throughout that assessment.
Ryoncil’s U.S. indication is much narrower: steroid-refractory acute graft-versus-host disease in children aged 2 months and older. In this complication of a donor transplant, donor immune cells attack the recipient’s tissues, and steroid treatment has not controlled the disease. The initial Ryoncil schedule involves eight intravenous infusions over four weeks, not a single universal treatment Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.
| Treatment | Evidence or approval scope | Delivery |
|---|---|---|
| Blood stem cell transplantation | Selected blood cancers, blood disorders, and immune disorders; eligibility is assessed individually Stem cell transplant | Infusion into a vein as part of a transplant treatment course |
| Ryoncil | U.S.: children aged 2 months and older with steroid-refractory acute graft-versus-host disease Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric | Repeated intravenous infusions |
| Temcell | Japan: acute graft-versus-host disease after allogeneic HSCT 000283257.pdf | Intravenous infusion |
| Nepic corneal epithelial cell sheet | Japan: corneal surface reconstruction in patients with limbal stem cell deficiency 000283257.pdf | Transplantation onto the eye surface |
Cell therapy is broader than stem cell therapy. The FDA’s combined cellular and gene therapy list also includes engineered immune-cell treatments and gene therapies. It is not a list of interchangeable stem cell treatments, and these examples are not a complete inventory of approved therapies Approved cellular and gene therapy products.
Japan’s newer treatments remain product-specific too. AMED reports that two separate iPS cell-derived products received conditional, time-limited approval on March 6, 2026: one for ischemic cardiomyopathy and one for Parkinson’s disease. Under this pathway, safety and a reasonable prediction of efficacy support initial approval, with further efficacy confirmation, safety evaluation, and reapplication required. This is not approval of a universal infusion 20260220.
Why one infusion is not proof
A shared cell label such as “MSC” does not make two treatments equivalent. A clinic needs evidence for its actual preparation and proposed use, not just a paper about cells with a similar name.
| What must match | Why it matters |
|---|---|
| Product and preparation | Approval of Ryoncil applies to that product, not to every donor-derived or patient-derived MSC preparation Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric. |
| Disease and patient group | Evidence for children with a transplant complication does not establish benefit for adults with arthritis or neurological disease Fda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric. |
| Route and outcome | A study of an intravenous treatment does not establish joint delivery or cartilage regrowth. Ryoncil’s label does not supply that evidence FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display. |
The FDA warns about unapproved regenerative medicine products marketed for a wide range of conditions. Clinic availability, company registration, and a ClinicalTrials.gov listing do not establish that a product is legally marketed or effective Important patient and consumer information about regenerative medicine therapies.
What research can and cannot show
Laboratory findings can suggest a mechanism, but they cannot establish patient benefit. Ryoncil’s label, for example, describes effects on T cells in laboratory studies separately from its clinical study. Human outcomes must be measured in people with the relevant disease FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display.
Knee osteoarthritis illustrates the limits. A 2025 Cochrane review, with searches current to September 15, 2023, included 25 randomized trials involving 1,341 participants. Eight trials involving 459 participants compared injections into the knee with placebo injections. At six months, the review reported average improvements of 1.2 points for pain on a 0–10 scale and 14.2 points for function on a 0–100 scale. The underlying pain and function analyses used seven trials each, with 445 and 432 participants respectively, and the certainty of evidence was low CD013342_what are benefits and risks stem cell injections knee osteoarthritis.
These results do not establish cartilage regrowth or a cure. No included trial assessed radiographic disease progression, and serious-harm estimates were very uncertain. Cell sources, preparation methods, and doses varied, so the average results cannot be assumed to apply to every clinic’s injection CD013342_what are benefits and risks stem cell injections knee osteoarthritis.
When comparing evidence by medical condition, check the comparison group, measured outcome, follow-up, and adverse events. A pain score is not a scan showing tissue repair. A study registry entry is a starting point for finding results, not the results themselves.
What Japanese paperwork actually proves
Japan has separate frameworks for product marketing approval under the Pharmaceuticals and Medical Devices Act and provision of regenerative medicine under the Act on the Safety of Regenerative Medicine. A provision plan is not a product marketing approval 0003.
MHLW’s public information includes provider names, treatment names, risk classifications, committee details, and patient information and consent documents. These records help identify what is being offered; a listing does not establish that the procedure is effective for your disease 0000186471.
If an offer says “approved in Japan,” ask whether that means a filed provision plan or a marketed product approval. Request the identifier and the exact treatment name. For a marketed product, check its approved indication; for a provision plan, examine the stated procedure and supporting human evidence rather than treating the plan number as proof of benefit.
What a cure-all offer can risk
The FDA has received reports of blindness, tumor formation, infections, and other harm following unapproved regenerative products. Its warning covers products obtained from a patient’s own body as well as from donors. Using your own cells does not remove contamination, inflammatory, or unintended-tissue risks Important patient and consumer information about regenerative medicine therapies. That is why safety checks for cell therapies offered in Japan need to address processing, delivery, and follow-up, not just the cell source.
Risks also differ by treatment. Graft-versus-host disease is a concern after allogeneic blood stem cell transplantation, not a risk that follows simply from a product containing donor cells. Ryoncil is used to treat steroid-refractory acute GVHD, while its own warnings include infusion reactions, transmission of infectious agents, and possible ectopic tissue formation Stem cell transplantFdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display.
Before delaying an established treatment, ask your treating physician what waiting could cost you. Payment for an unproven procedure is not the only possible loss; missed treatment opportunities matter too.
How to check a multi-disease offer
Suppose a quote offers one intravenous MSC preparation for both knee osteoarthritis and Parkinson’s disease. These are two separate evidence questions. A knee-injection trial does not validate an intravenous treatment for either condition, and Ryoncil’s approval for a transplant complication does not fill that gap CD013342_what are benefits and risks stem cell injections knee osteoarthritisFda approves remestemcel l rknd steroid refractory acute graft versus host disease pediatric.
Before arranging treatment in Japan, put the quote beside the proposed treatment documents and ask for written answers:
- What is my exact diagnosis, and what measurable problem is this treatment intended to improve?
- What cell type, source, processing method, dose, route, and number of treatments would I receive?
- Is this an approved product, a procedure under a provision plan, or a clinical trial? Which identifier can I verify?
- Which published human study matches my disease, patient group, cell preparation, and route? What were its sample size, comparison group, outcomes, follow-up, and adverse events?
- What are the known and uncertain harms, who manages complications, and what monitoring is included?
- What established options might I delay, what is the full cost, and when would we decide whether treatment has helped?
Keep the answers for a discussion with a licensed physician familiar with your condition who is not selling the proposed procedure. A product name or plan number makes a claim easier to check; it does not, by itself, answer whether you are likely to benefit.
Have questions about treatment arrangements in Japan?
Ask the patient support team about the information needed for an inquiry. Support with arrangements is not an independent medical assessment or a guarantee of eligibility or benefit.
Can one treatment cover every disease?
No. Some cell treatments have established uses, and others remain experimental. Neither a successful use for one disease nor permission to provide a procedure proves a universal benefit. Judge each offer by its specific product, diagnosis, route, human outcomes, and risks.
This article explains public scientific and regulatory documents. It does not report first-hand treatment experience and is not individual medical advice. Treatment decisions require a licensed physician’s assessment of your records.
Sources
- NCI: Stem Cell Transplants in Cancer Treatment
- FDA: Ryoncil approval, efficacy, safety, and dosing, December 18, 2024
- NIH: Stem Cell Basics
- DailyMed: Ryoncil prescribing information
- PMDA: List of Approved Products, April 2015 to July 2026
- FDA: Approved Cellular and Gene Therapy Products
- AMED: Japan’s iPS cell therapy applications and conditional approval pathway, updated March 23, 2026
- FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies, updated April 8, 2024
- Cochrane: Stem cell injections for osteoarthritis of the knee, 2025; searches through September 15, 2023
- PMDA: Regenerative Medical Products regulatory frameworks
- MHLW: Public information on providers of regenerative medicine




